Belli, Stefania http://orcid.org/0000-0002-8348-3313
Esposito, Daniela http://orcid.org/0000-0001-5211-9861
Allotta, Alessandra http://orcid.org/0000-0002-7684-2031
Servetto, Alberto
Ciciola, Paola
Pesapane, Ada
Ascione, Claudia M.
Napolitano, Fabiana http://orcid.org/0000-0002-2463-8952
Di Mauro, Concetta
Vigliar, Elena
Iaccarino, Antonino
De Angelis, Carmine
Bianco, Roberto
Formisano, Luigi http://orcid.org/0000-0001-7205-5105
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (MFAG 21505 - 2018, Fellowship for Italy 2021 - 6795, IG 21339)
Eli Lilly and Company
Article History
Received: 7 June 2022
Accepted: 23 May 2023
First Online: 31 May 2023
Competing interests
: L.F. declares the following competing interests: consultant and advisory board for Seagen, Amgen, BMS, MSD, Jansen and Pierre Fabre Pharma. R.B. declares the following competing interests: consultant and advisory board for BMS, MSD, Pfizer, AstraZeneca, Lilly and Novartis.